Last reviewed · How we verify
Eliquis — patents & exclusivity
Apixaban selectively inhibits Factor Xa, decreasing thrombin generation and thrombus development.
Patents
| Number | Expiry | Type | Status |
|---|---|---|---|
| Active | |||
| Active | |||
| Active | |||
| Active | |||
| 9326945 | 2031-02-24 | Formulation | |
| 9326945*PED | 2031-08-24 | Compound |
See also
- Full profile: Eliquis
- Side effects: /side-effects
- Dosage & administration: /dosage
- Mechanism of action: /mechanism
- Cost & pricing: /cost
- Drug interactions: /interactions
- Clinical trials: /clinical-trials
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing